Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a Form 8-K reporting events occurring on or around April 4, 2023. The filing concerns a registered direct offering, related warrant amendments, and an April 5, 2023 press release. The report was signed April 6, 2023.
Financing and Key Financial Terms
- Celularity agreed to issue 9,230,770 shares of Class A common stock and warrants to purchase up to 9,230,770 additional shares.
- The combined purchase price was $0.65 per share and accompanying warrant, for aggregate gross proceeds of approximately $6.0 million.
- The offering was expected to close on or about April 10, 2023, subject to customary closing conditions.
- The new warrants have an exercise price of $0.75 per share, become exercisable six months after issuance, and expire five years after the initial exercise date.
- Warrant exercises are subject to customary adjustments and beneficial ownership limitations of 4.99%, or 9.99% if elected by the holder.
- A.G.P./Alliance Global Partners is the exclusive placement agent and will receive a cash fee equal to 7% of gross proceeds, plus reimbursement of up to $75,000 of legal expenses.
Material Changes and Unusual Items
- Existing warrants to purchase up to 4,054,055 shares were amended, subject to the offering closing.
- The amended warrants’ exercise price was reduced from $8.25 to $0.75 per share.
- The amended warrants’ termination date was changed from May 20, 2027 to five and one-half years following the offering closing.
- The issuance of new shares and warrants, together with the repricing of existing warrants, may materially increase potential share dilution.
Use of Proceeds, Outlook, and Risks
Celularity intends to use net proceeds for working capital and general corporate purposes, including repayment of obligations under a September 15, 2022 pre-paid advance agreement with YA II PN, Ltd.
The filing does not provide revenue, profit, cash flow, margin, debt-balance, liquidity, or operating guidance metrics. Closing remains subject to customary conditions, and the actual net proceeds will be reduced by placement-agent fees and expenses. The filing text does not state whether the offering ultimately closed.
Important Facts for Investors to Verify
- Whether the offering closed on or about April 10, 2023 and the final net proceeds received.
- The number of shares outstanding after the offering and the resulting dilution to existing holders.
- The final terms and outstanding balance of the YA II PN, Ltd. pre-paid advance obligations.
- The effect of repricing 4,054,055 existing warrants from $8.25 to $0.75 on potential future dilution.
- The full Purchase Agreement, warrant forms, placement agency agreement, and warrant amendment filed as Exhibits 10.1 through 10.4.